We are live on ! Find out more
FHTX icon

Foghorn Therapeutics
FHTX

87 hedge funds and large institutions have $190M invested in Foghorn Therapeutics in 2024 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 12

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

10% more funds holding

Funds holding: 79 → 87 (+8)

0.12% more ownership

Funds ownership: 72.29% → 72.41% (+0.12%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

49% less capital invested

Capital invested by funds: $372M → $190M (-$182M)

Holders
87
Holders Change
+8
Holders Change %
+10.13%
% of All Funds
1.15%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
32
Reduced
12
Closed
8
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
-$66K

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.71M
2
DM
Deerfield Management
New York
+$1.66M
3
BlackRock
BlackRock
New York
+$1.59M
4
DCM
DAFNA Capital Management
California
+$1.09M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$688K

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.69M
2
Citadel Advisors
Citadel Advisors
Florida
-$756K
3
BCM
Bridgeway Capital Management
Texas
-$182K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$173K
5
Jane Street
Jane Street
New York
-$173K
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$59.8M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$26.9M -$4.69M -644,265 -10%
BI
3
BVF Inc
California
$25M – – –
DM
4
Deerfield Management
New York
$15.4M +$1.66M +227,628 +8%
Raymond James Financial
5
Raymond James Financial
Florida
$9.58M +$14.8M +2,029,383 New
BlackRock
6
BlackRock
New York
$9.58M +$1.59M +217,906 +12%
Vanguard Group
7
Vanguard Group
Pennsylvania
$8.26M +$129K +17,681 +1%
EC
8
Euclidean Capital
New York
$7.43M – – –
SL
9
Siren LLC
Connecticut
$3.4M – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$3.22M +$39.9K +5,477 +0.8%
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$3M +$1.71M +235,059 +59%
State Street
12
State Street
Massachusetts
$2.68M +$447K +61,422 +12%
AI
13
Alphabet Inc
California
$2.36M – – –
BC
14
Birchview Capital
Vermont
$1.47M -$72.8K -10,000 -3%
Northern Trust
15
Northern Trust
Illinois
$1.2M +$20.9K +2,873 +1%
Jacobs Levy Equity Management
16
Jacobs Levy Equity Management
New Jersey
$1.06M +$688K +94,449 +73%
DCM
17
DAFNA Capital Management
California
$881K +$1.09M +149,053 +396%
SCM
18
Sio Capital Management
New York
$574K – – –
RWM
19
Rockwood Wealth Management
Pennsylvania
$495K – – –
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$474K +$223K +30,671 +44%
Morgan Stanley
21
Morgan Stanley
New York
$460K -$77.6K -10,656 -10%
Millennium Management
22
Millennium Management
New York
$437K +$250K +34,306 +59%
Wellington Management Group
23
Wellington Management Group
Massachusetts
$411K +$108K +14,853 +21%
Charles Schwab
24
Charles Schwab
California
$356K – – –
Goldman Sachs
25
Goldman Sachs
New York
$352K +$212K +29,099 +64%
1
2 3 4

FHTX Hedge Fund Activity: Q4 2024 in Review

87 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q4 2024, worth a combined $190M — down 49% from $372M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new FHTX positions and 8 closed out — a net gain of 9 holders — while 32 added to existing stakes and 12 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $1.71M. The largest seller was Fidelity Investments, cutting an estimated $4.69M.

  • 87 institutional investors held Foghorn Therapeutics (FHTX) as of Q4 2024, up from 79 in Q3 2024.
  • Funds reported $190M of Foghorn Therapeutics stock for Q4 2024, down 49% quarter-over-quarter.
  • 17 funds opened new Foghorn Therapeutics positions in Q4 2024 and 8 closed out, a net change of +9 holders.
  • The largest Foghorn Therapeutics buyer in Q4 2024 was Point72 Asset Management, an estimated $1.71M added.
  • The largest Foghorn Therapeutics seller in Q4 2024 was Fidelity Investments, an estimated $4.69M sold.

Based on aggregated 13F filings for Q4 2024.